About RejuvaTech
An innovation-driven platform company specializing in patent-protected longevity chemistry, advanced absorption systems, and scalable GMP integration.
Filed IP Platforms for Next-Generation NAD+ Precursors, Advanced Absorption, and Premium Longevity Innovation
About RejuvaTech
RejuvaTech LLC is a research-driven platform company focused on filed intellectual property for next-generation NAD+ precursor technologies, BioPeak® advanced absorption systems, stabilized longevity actives, and premium wellness product architecture.
The company’s work is designed for qualified strategic partners seeking differentiated product platforms across pharmacy, health-beauty, longevity, nutraceutical, and premium dietary supplement markets.
RejuvaTech’s objective is not to create ordinary supplement formulas. Its objective is to develop protected platform technologies capable of supporting higher-value product classes, improved active-ingredient delivery, and commercially defensible premium wellness portfolios.
RejuvaTech’s core platform areas include:
Strategic Platform Focus
BioPeak®-NAD
Advanced absorption architecture designed to improve selected active-ingredient delivery and support differentiated product positioning across NAD+ support, mitochondrial energy, beauty-from-within, antioxidant defense, polyphenol longevity, metabolic wellness, and other high-value categories.
RiboGEN® Platform
Next-generation NR-related technologies designed to support differentiated NAD+ precursor positioning and alternative product-development pathways.
RiboGEN® II
Stabilized NRH platform technology intended to support future NAD+ precursor innovation beyond conventional NR, NMN, and commodity NAD+ product formats.
BioPeak®-TR
Advanced triterpenoid delivery platform designed for selected skin, beauty-from-within, mobility, botanical longevity, and health-beauty product applications.
Together, these platforms are intended to help qualified partners move beyond commodity ingredient competition and toward proprietary absorption-platform and protected-chemistry product classes.
Longevity Chemistry & Regenerative Platform Research
Bret M. Lee / Founder & Chief Scientist, RejuvaTech LLC
Bret M. Lee is the Founder and Chief Scientist of RejuvaTech LLC. His work focuses on protected longevity chemistry, next-generation NAD+ precursor systems, advanced oral delivery architecture, triterpenoid platform development, formulation strategy, and commercial product differentiation.
Mr. Lee has more than four decades of experience across chemistry, cellular biology, natural product research, product development, and commercialization strategy. His current work is centered on building filed IP platforms that can support premium wellness, pharmacy, nutraceutical, and health-beauty product innovation.
At RejuvaTech, he leads the development and strategic commercialization of filed non-provisional IP platforms covering BioPeak®-NAD, RiboGEN® next-generation NR, RiboGEN® II stabilized NRH, and BioPeak®-TR technologies.
His focus is the creation of institution-ready platform assets that can be evaluated through structured corporate diligence and, where appropriate, advanced through acquisition, licensing, co-development, manufacturing, or platform-commercialization pathways.